MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)

BACKGROUND: Doublet chemotherapy in combination with a biologic agent has been a standard of care in patients with metastatic colorectal cancer for over a decade. The evidence for a “lighter” treatment approach is limited to mono-chemotherapy plus bevacizumab in the RAS unselected population. Anti-E...

Descripción completa

Detalles Bibliográficos
Autores principales: Siu, Ho Wai Derrick, Tebbutt, Niall, Chantrill, Lorraine, Karapetis, Chris, Steer, Christopher, Wilson, Kate, Espinoza, David, Bailey, Lisa, Yip, Sonia, Cuff, Jeff, Pavlakis, Nick, Thavaneswaran, Subotheni, Briscoe, Karen, Srivastav, Ratnesh, Shannon, Jennifer, Segelov, Eva, Tie, Jeannie, Caird, Susan, Francesconi, Alessandra, Price, Timothy, Wuttke, Melanie, Ladwa, Rahul, Sjoquist, Katrin, Burge, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371602/
https://www.ncbi.nlm.nih.gov/pubmed/34407800
http://dx.doi.org/10.1186/s12885-021-08644-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371602/
https://www.ncbi.nlm.nih.gov/pubmed/34407800
http://dx.doi.org/10.1186/s12885-021-08644-4

Ejemplares similares